Aprogen Biologics plans capital increase
에이프로젠바이오로직스
003060
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2547
Risk-adjusted indicator based on 2547 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Board Resolution Date: July 14, 2026
- • G-Base Co., Ltd. (Max Shareholder of Nexconics): Asset Total 21,370M KRW (2025)
- • G-Base Co., Ltd. (Max Shareholder of Nexconics): Revenue 1,720M KRW (2025)
- • G-Base Co., Ltd. (Max Shareholder of Nexconics): Net Income -43M KRW (2025)
AI Analysis Summary
Aprogen Biologics Inc. has announced a decision for a paid-in capital increase, with the board resolution dated July 14, 2026. While specific details regarding the number of new shares, issuance price, and total funding amount are not yet disclosed, the report indicates the purpose of funds will be specified later. Information on G-Base Co., Ltd., a major shareholder of Nexconics (95.24% stake), shows its 2025 financials with total assets of 21,370M KRW, revenue of 1,720M KRW, and a net loss of 43M KRW. The impact on existing shareholders will depend on the final terms of the issuance.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.